Accepting New Patients
Fataneh Majlessipour, MD
Fax: 310-967-1141
From You
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Languages
- English,
- Farsi,
Gender
Female
Experience
32 Years
Locations
Samuel Oschin Cancer Center
Samuel Oschin Cancer Center
-
Self-parking is available in Cedars-Sinai parking lot P4. The cost is: 1st hour free, $5 each hour thereafter and $15 daily maximum. Valet parking is the same price as self-parking. Gratuities are not accepted. Valet is available at lot P4 Pavilion M-F, 5 a.m.-10 p.m.
Experience
Specialties
Area in which a healthcare provider is highly trained and often board certified.
1
- Peds Hematology Oncology
Programs
Cedars-Sinai clinical programs this provider is part of:
3
Research Areas
Titles
- Director, Division of Pediatric Hematology/Oncology
Education & Training
-
Children's Hospital Los Angeles
Residency - Completed 2000
-
Children's Hospital of Orange County
Residency - Completed 1997
-
Isfahan University of Medical Sciences Iran
Medical School - Completed 1990
Achievements
-
2
Board Certifications
-
4
Awards and Honors
Board Certifications
-
Pediatrics
American Board of Pediatrics
-
Pediatric Hematology-Oncology
American Board of Pediatrics
Awards and Honors
- Hollywood Top Doctors
- Southern California Super Doctors
- Best Doctors of Los Angeles
- Los Angeles Top Doctors
Publications
- Chan, J, Kashanian, A, Bannykh, S, Majlessipour, F, Breunig, J, Danielpour, M RELA Fusion-Positive Ependymoma in a Child with Down Syndrome: Case Report. Accepted in August 2020 for publication in Pediatric Neurosurgery.
- Rao RR, Majlessipour F, Ziring DA, Baca NM. Ewing's Sarcoma in a Patient with Crohn's Disease Treated with Ustekinumab: A Case Report. J Adolesc Young Adult Oncol. 2020 Sep 22. doi: 10.1089/jayao.2020.0077.
- Miller JM, Wachsman A, Haker K, Majlessipour F, Danielpour M, Puliyanda D. The effects of everolimus on tuberous sclerosis-associated lesions can be dramatic but may be impermanent. Pediatr Nephrol. 2015 Jan; 30(1):173-7.
- . Gidrewics D, Rabizadeh S, Lehman D, Majlessipour F, Dubinsky M. Primary EBV infection resulting in Lymphoproliferative disease in a teenager with Crohn’s disease. Journal of Pediatric Gastroenterology & Nutrition, 2010
- Baron PW, Majlessipour F, Bedros AA, Zuppan CW, Ben-Youssef R, Yanni G, Ojogho ON, and Concepcion W. Undifferentiated Embryonal sarcoma of the liver successfully treated with chemotherapy; and liver resection. J of Gastrointestinal Surgery Vol11, Number 1, January 2007, pages: 73-75
- Avramis VI, Sencer S, Periclou P, Sather H, Bostrom B, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon P, Hilden JM, Lange B, Majlessipour F, Pracad M, Needle M, Neglia J, Reaman G, Holcenberg JS. A randomized comparison of Native E. Coli asparaginase and polyethylene glycol conjugated asparaginase for the treatment of children with newly diagnosed standard-risk acute lymphoblastic Leukemia: A Children’s Cancer Group study. Blood 99(6):1986-1994 (2002).
- Majlessipour F, Avramis IA, Kwock R, Weinberg KI, Avramis VI. The Combination Regimen of Idarubicin and Taxotere is effective Against Human Drug-Resistant Leukemic Cell Lines. Anticancer Research 22:1361-1368 (2002).
- Majlessipour F, Kwock R, Martin-Aragon S, Weinberg KI, Avramis VI. Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities. Anticancer Research 21:11-22 (2001).
Insurances
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Cedars-Sinai location or provider is included in your network.